IDXX Stock Recent News

Idexx (IDXX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Morgan Stanley raised the firm's price target on Idexx Laboratories to $722 from $626 and keeps an Overweight rating on the shares. Following the Q2 results, what "stood out to us" was accelerating consumables growth globally as well as an expanding inVue installed base, the analyst tells investors. An expanding installed base and share gains set the stage for accelerating growth when the market normalizes, the analyst contends.

Major U.S. equities indexes pushed higher at the top of the new trading week, bouncing back from declines posted ahead of the weekend. Although weaker-than-expected jobs data released on Friday raised concerns about the resilience of the economy, the slowdown in hiring and uptick in unemployment could add to the case for upcoming interest-rate cuts by the Federal Reserve.

IDEXX Laboratories, Inc. (NASDAQ:IDXX ) Q2 2025 Earnings Conference Call August 4, 2025 8:30 AM ET Company Participants Andrew Emerson - Executive VP, CFO & Treasurer Jonathan J. Mazelsky - President, CEO & Director Conference Call Participants Christopher Thomas Schott - JPMorgan Chase & Co, Research Division Daniel Christopher Clark - Leerink Partners LLC, Research Division David Michael Westenberg - Piper Sandler & Co., Research Division Erin Elizabeth Wilson Wright - Morgan Stanley, Research Division Jonathan David Block - Stifel, Nicolaus & Company, Incorporated, Research Division Michael Leonidovich Ryskin - BofA Securities, Research Division Navann Ty Dietschi - BNP Paribas Exane, Research Division Ryan Scott Daniels - William Blair & Company L.L.C.

The Investment Committee gives you their top stocks to watch for the second half.

U.S. equities were higher at midday, bouncing back from Friday's employment report-related selloff, and on news the European Union would delay new tariffs on U.S. goods. The Dow Jones Industrial Average, S&P 500, and Nasdaq all rose.

IDXX posts double-digit Q2 revenue growth, beats EPS estimates and lifts the full-year outlook as margins rise sharply.

Pet healthcare is witnessing a surge in demand as more households prioritize their pets' well-being, driving companies in this sector to outperform expectations. This trend is reflected in IDEXX Laboratories Inc.‘s IDXX recent financial results, showcasing significant growth and revised earnings guidance.